Key result
NOACs show comparable in-hospital mortality to warfarin in ED patients with GI bleeding.
Why the study?
GI bleeding is an important complication of oral anticoagulation, but real-world data comparing short-term clinical outcomes following GI bleeding in patients receiving warfarin versus NOACs are limited.
Do NOACs improve short-term clinical outcomes compared to warfarin in anticoagulated patients with GI bleeding?
Cross-Sectional (n=299)
No
Do NOACs improve short-term clinical outcomes compared to warfarin in anticoagulated patients with GI bleeding?
Comparable mortality in Level 5 data warrants no practice change; leaves open whether NOACs improve outcomes versus warfarin.
zAma: Gastrointestinal (GI) kanama, oral antikoaglan tedavisinin nemli bir komplikasyonudur.Vitamin K iermeyen oral antikoaglanlar (NOAC) warfarine gre avantajlar sunsa da antikoaglan tedavisi gren hastalarda GI kanama olaylarn takiben ksa vadeli klinik sonular karlatran snrl sayda gerek dnya verisi bulunmaktadr.
No takes yet. Share an insight, caveat, or question.
Sorgun et al. (2025) conducted a cross-sectional in Gastrointestinal bleeding on oral anticoagulants (n=299). NOACs vs. Warfarin was evaluated on In-hospital mortality (p=0.855). NOACs demonstrated comparable in-hospital mortality rates (7.2%) to warfarin (7.8%) in patients presenting to the emergency department with gastrointestinal bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: